The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
Probiodrug changes its name to Vivoryon and expands its focus to include oncology, but insists that it is still first and foremost an Alzheimer’s company.
Positive data, toxicity, a US FDA delay and the early leaking of information culminate in a green light for the multiple myeloma drug.
Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
After a quiet first quarter demand for new issues has returned to levels seen in 2018, itself a record year for IPOs of young drug developers.
A delayed decision on Karyopharm’s selinexor is the pick of the bunch for July.
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?